Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors

被引:5
作者
Sakin, Abdullah [1 ]
Can, Orcun [2 ]
Arici, Serdar [2 ]
Yasar, Nurgul [2 ]
Geredeli, Caglayan [2 ]
Demir, Cumhur [2 ]
Cihan, Sener [2 ]
机构
[1] Yuzuncu Yil Univ, Dept Med Oncol, Med Sch, Van, Turkey
[2] Univ Hlth Sci, Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey
关键词
Gastrointestinal stromal tumor; Disease-free survival; Imatinib; Overall survival; PROGNOSTIC-FACTORS; DIAGNOSIS; IMATINIB; GISTS; ERA; EPIDEMIOLOGY; EXPERIENCE; KIT;
D O I
10.1016/j.jss.2019.03.059
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Possibly originating from interstitial Cajal cells, gastrointestinal stromal tumors (GISTS) have variable biological behaviors. In this study, we aimed to examine the factors affecting the disease-free survival (DFS) in patients with GIST who underwent operation. Material and methods: The study included the patients who were followed up and treated for GIST in our oncology clinic between 2002 and 2017. The Armed Forces Institute of Pathology criteria (Miettinen risk score) were used for risk stratification of patients. Results: Seventy-four patients were included to the study, where female patients constituted 52.7%, and the median age was 56 (range: 24-83) y. Most common primary tumor location was the stomach (51.4%), followed by the small intestine (33.8%), colorectum (10.8%), and retroperitoneum (4.1%). Miettinen risk score showed 12 patients (16.7%) at very low risk, 15 patients (20.8%) at low risk, 18 patients (25%) at intermediate risk, and 27 patients (37.5%) at high risk. DFS was significantly lower in patients with small intestine involvement than in cases with stomach involvement (P = 0.004). DFS was significantly lower in patients at high risk than in patients with no high risk (P = 0.034). Small intestine localization (hazard ratio [HR], 8.98; 95% confidence interval [CI], 1.14-8.18), high-risk score (HR, 5.16; 95% CI, 1.42-12.75), c-kit positivity (HR, 0.24; 95% CI, 0.13-0.69), and adjuvant therapy (HR, 0.37; 95% CI, 0.20-0.92) were found to be the most significant factors affecting DFS. Conclusions: Our study showed negative effects of small intestine localization and high-risk category and positive effects of c-kit positivity and adjuvant therapy on DFS in patients with GIST who underwent operation. When a decision will be made in favor of adjuvant therapy, tumor localization and c-kit mutation should also be considered in addition to risk score. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 33 条
  • [21] Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466
  • [22] Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor
    Yoshihide Nagasako
    Kazuhito Misawa
    Shigechika Kohashi
    Kimiharu Hasegawa
    Yumi Okawa
    Hidekazu Sano
    Akio Takada
    Hidetoshi Sato
    [J]. Gastric Cancer, 2003, 6 (3) : 168 - 172
  • [23] GASTROINTESTINAL STROMAL TUMORS - CORRELATION OF IMMUNOPHENOTYPE WITH CLINICOPATHOLOGICAL FEATURES
    NEWMAN, PL
    WADDEN, C
    FLETCHER, CDM
    [J]. JOURNAL OF PATHOLOGY, 1991, 164 (02) : 107 - 117
  • [24] Gastrointestinal stromal tumors:: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era -: A population-based study in western Sweden
    Nilsson, B
    Bümming, P
    Meis-Kindblom, JM
    Odén, A
    Dortok, A
    Gustavsson, B
    Sablinska, K
    Kindblom, LG
    [J]. CANCER, 2005, 103 (04) : 821 - 829
  • [25] Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential
    Özgüç, H
    Yilmazlar, T
    Yerci, O
    Soylu, R
    Tümay, V
    Filiz, G
    Zorluoglu, A
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2005, 9 (03) : 418 - 429
  • [26] Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis
    Pyo, Jung-Soo
    Kang, Guhyun
    Sohn, Jin Hee
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2016, 31 (02) : E204 - E210
  • [27] Rubin BP, 2001, CANCER RES, V61, P8118
  • [28] Prognostic Factors in Gastrointestinal Stromal Tumors: Multicenter Experience of 333 Cases from Turkey
    Seker, Mesut
    Sevinc, Alper
    Yildiz, Ramazan
    Cihan, Sener
    Kaplan, Mehmet Ali
    Gokdurnali, Ayse
    Dane, Faysal
    Yaman, Emel
    Karaca, Halit
    Colak, Dilsen
    Uyeturk, Ummugul
    Bilici, Ahmet
    Ozdemir, Nuriye Yildirim
    Kalender, Mehmet Emin
    Uncu, Dogan
    Salepci, Taflan
    Isikdogan, Abdurrahman
    Benekli, Mustafa
    Ozkan, Metin
    Gumus, Mahmut
    Coskun, Ugur
    Camci, Celalettin
    Oksuzoglu, Berna
    Buyukberber, Suleyman
    [J]. HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 768 - 775
  • [29] Gastrointestinal Stromal Tumors in Turkey: Experiences from 3 Centers
    Selcukbiricik, Fatih
    Yalcin, Suayip
    Tural, Deniz
    Erdamar, Sibel
    Demir, Gokhan
    Dogusoy, Gulen
    Mandel, Nil Molinas
    [J]. ONKOLOGIE, 2013, 36 (1-2): : 18 - 24
  • [30] A guide for the diagnosis and management of gastrointestinal stromal cell tumors
    Sepe, Paul S.
    Brugge, William R.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (06) : 363 - 371